In contrast to its wild-type counterpart, mutant p53 in cancer cells regulates and inhibits the tumor-suppressive response to IFN-β via inhibiting STAT1 phosphorylation and downstream targets of IFN-β. Here, IFNB1 is linked to neoplasm.